An adaptive trial of neoadjuvant therapy for high-risk HER2 BC patients suggested that neratinib was highly likely to result in higher rates of pCR when added to standard chemotherapy with trastuzumab among patients with HER2+/ER- BC. This evidence concerns the gene ERBB2 and breast cancer.